1. Home
  2. GRF vs PRPO Comparison

GRF vs PRPO Comparison

Compare GRF & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eagle Capital Growth Fund Inc.

GRF

Eagle Capital Growth Fund Inc.

N/A

Current Price

$10.20

Market Cap

41.0M

Sector

Finance

ML Signal

N/A

Logo Precipio Inc.

PRPO

Precipio Inc.

HOLD

Current Price

$30.44

Market Cap

44.4M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
GRF
PRPO
Founded
1989
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Laboratory Analytical Instruments
Sector
Finance
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
41.0M
44.4M
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
GRF
PRPO
Price
$10.20
$30.44
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.9K
14.9K
Earning Date
01-01-0001
05-12-2026
Dividend Yield
3.70%
N/A
EPS Growth
N/A
92.15
EPS
1.16
N/A
Revenue
N/A
$24,049,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$8.80
N/A
Revenue Growth
N/A
29.77
52 Week Low
$9.50
$6.29
52 Week High
$11.85
$33.63

Technical Indicators

Market Signals
Indicator
GRF
PRPO
Relative Strength Index (RSI) 49.27 51.58
Support Level $9.60 $22.96
Resistance Level $10.61 $29.66
Average True Range (ATR) 0.16 2.41
MACD 0.03 -0.04
Stochastic Oscillator 63.76 46.51

Price Performance

Historical Comparison
GRF
PRPO

About GRF Eagle Capital Growth Fund Inc.

Eagle Capital Growth Fund Inc is a diversified closed-end investment company. The Fund's objective is long-term growth utilizing the concept of total return for selecting investments. It seeks to achieve its investment objectives by investing predominantly in U.S. issuer common stock, giving preference to high-quality companies, where high quality denotes substantial operating income margins, high returns on capital, and robust balance sheets.

About PRPO Precipio Inc.

Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.

Share on Social Networks: